Policy & Regulation
Natera and Aveta Biomics partner on Phase 3 head and neck cancer trial
29 June 2026 - Cell-free DNA and precision medicine company Natera Inc (NASDAQ: NTRA) and Aveta Biomics Inc, a clinical-stage immuno-oncology company, on Monday announced a strategic partnership to su...
AbbVie receives positive CHMP opinion for upadacitinib in severe alopecia areata
29 June 2026 - US biopharmaceutical company AbbVie (NYSE: ABBV) said on Monday it has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human U...
Neurogene reports durable positive long-term results from NGN-401 gene therapy in Rett syndrome trial
29 June 2026 - Genetic medicine company Neurogene Inc (NASDAQ: NGNE) on Monday reported updated positive long-term clinical data from its Phase 1/2 trial of NGN-401 gene therapy in females with Rett s...
Evommune reports Phase 2b trial miss for EVO756 in chronic spontaneous urticaria
29 June 2026 - Biotechnology company Evommune Inc (NYSE: EVMN) disclosed on Monday that its Phase 2b trial evaluating EVO756 in moderate-to-severe chronic spontaneous urticaria did not meet its primar...
AbbVie receives positive CHMP opinion for upadacitinib in non‑segmental vitiligo
29 June 2026 - US biopharmaceutical company AbbVie (NYSE: ABBV) announced on Monday it has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Hu...
AstraZeneca's Datroway recommended for EU approval as first-line treatment in metastatic triple-negative breast cancer
29 June 2026 - Biopharmaceutical company AstraZeneca PLC (LSE: AZN) (STO: AZN) (NYSE: AZN), announced on Monday that together with Daiichi Sankyo Company Limited, it has received a positive recommenda...